News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ascepion Pharmaceuticals, Inc. and Debiopharm to Develop Cancer Drug for China


4/18/2013 11:29:37 AM

by Richard Daverman, PhD

April 18, 2013 -- Suzhou Ascepion Pharma announced that Debiopharm of Switzerland will support further China development of Debio 1144, a small molecule in preclinical development as a treatment for solid tumors. In June 2012, Ascepion out-licensed global rights for the molecule to Debiopharm. Because the drug has the potential to be an effective treatment for cancers that are prevalent in China, Debiopharm will support Ascepion’s development of Debio 1144 for China. Terms were not disclosed. More details....


Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES